Literature DB >> 9804619

Evidence for involvement of mitogen-activated protein kinase, rather than stress-activated protein kinase, in potentiation of 1-beta-D-arabinofuranosylcytosine-induced apoptosis by interruption of protein kinase C signaling.

W D Jarvis1, F A Fornari, R M Tombes, R K Erukulla, R Bittman, G K Schwartz, P Dent, S Grant.   

Abstract

The stress-activated protein kinase (SAPK) and mitogen-activated protein kinase (MAPK) cascades mediate cytotoxic and cytoprotective functions, respectively, in the regulation of leukemic cell survival. Involvement of these signaling systems in the cytotoxicity of 1-beta-D-arabinofuranosylcytosine (ara-C) and modulation of ara-C lethality by protein kinase C PKC inhibition/down-regulation was examined in HL-60 promyelocytic leukemia cells. Exposure to ara-C (10 microM) for 6 hr promoted extensive apoptotic DNA damage and cell death, as well as activation of PKC. This response was accompanied by downstream activation of the SAPK and MAPK cascades. PKC-dependent MAPK activity seemed to limit ara-C action in that the toxicity of ara-C was enhanced by pharmacological reductions of PKC, MAPK, or both. Thus, ara-C action was (1) partially attenuated by diradylglycerols, which stimulated PKC and MAPK, but (2) dramatically amplified by sphingoid bases, which inhibited PKC and MAPK. The cytotoxicity of ara-C also was substantially increased by pharmacological reductions of PKC, including down-regulation of PKC by chronic preexposure to the macrocyclic lactone bryostatin 1 or inhibition of PKC by acute coexposure to the dihydrosphingosine analog safingol. Significantly, both of these manipulations prevented activation of MAPK by ara-C. Moreover, acute disruption of the MAPK module by AMF, a selective inhibitor of MEK1, suppressed both basal and drug-stimulated MAPK activity and sharply increased the cytotoxicity of ara-C, suggesting the direct involvement of MAPK as a downstream antiapoptotic effector for PKC. None of these chemopotentiating agents enhanced ara-CTP formation. Ceramide-driven SAPK activity did not seem to mediate drug-induced apoptosis, given that (1) neutralization of endogenous tumor necrosis factor-alpha with monoclonal antibodies or soluble tumor necrosis factor receptor substantially reduced ceramide generation and SAPK activation by ara-C, whereas the induction of apoptosis was unaffected; (2) pharmacological inhibition of sphingomyelinase by 3-O-methoxysphingomyelin reduced ceramide generation and SAPK activation without limiting the drug's cytotoxicity; and (3) potentiation of ara-C action by bryostatin 1 or safingol was not associated with further stimulation of SAPK. These observations collectively suggest a primary role for decreased MAPK, rather than increased SAPK, in the potentiation of ara-C cytotoxicity by interference with PKC-dependent signaling.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9804619     DOI: 10.1124/mol.54.5.844

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  15 in total

1.  Deoxycholic acid (DCA) causes ligand-independent activation of epidermal growth factor receptor (EGFR) and FAS receptor in primary hepatocytes: inhibition of EGFR/mitogen-activated protein kinase-signaling module enhances DCA-induced apoptosis.

Authors:  L Qiao; E Studer; K Leach; R McKinstry; S Gupta; R Decker; R Kukreja; K Valerie; P Nagarkatti; W El Deiry; J Molkentin; R Schmidt-Ullrich; P B Fisher; S Grant; P B Hylemon; P Dent
Journal:  Mol Biol Cell       Date:  2001-09       Impact factor: 4.138

2.  Roles for basal and stimulated p21(Cip-1/WAF1/MDA6) expression and mitogen-activated protein kinase signaling in radiation-induced cell cycle checkpoint control in carcinoma cells.

Authors:  J S Park; S Carter; D B Reardon; R Schmidt-Ullrich; P Dent; P B Fisher
Journal:  Mol Biol Cell       Date:  1999-12       Impact factor: 4.138

3.  Therapeutic targeting of the MEK/MAPK signal transduction module in acute myeloid leukemia.

Authors:  M Milella; S M Kornblau; Z Estrov; B Z Carter; H Lapillonne; D Harris; M Konopleva; S Zhao; E Estey; M Andreeff
Journal:  J Clin Invest       Date:  2001-09       Impact factor: 14.808

Review 4.  Protein kinase C targeting in antineoplastic treatment strategies.

Authors:  W D Jarvis; S Grant
Journal:  Invest New Drugs       Date:  1999       Impact factor: 3.850

Review 5.  Potential role of sorafenib in the treatment of acute myeloid leukemia.

Authors:  Shahram Mori; Jorge Cortes; Hagop Kantarjian; Weiguo Zhang; Michael Andreef; Farhad Ravandi
Journal:  Leuk Lymphoma       Date:  2008-12

6.  Hydrophilic interaction liquid chromatography-tandem mass spectrometric approach for simultaneous determination of safingol and D-erythro-sphinganine in human plasma.

Authors:  Hwang Eui Cho; Barry J Maurer; C Patrick Reynolds; Min H Kang
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2019-02-22       Impact factor: 3.205

Review 7.  Overcoming resistance to molecularly targeted anticancer therapies: Rational drug combinations based on EGFR and MAPK inhibition for solid tumours and haematologic malignancies.

Authors:  Giampaolo Tortora; Roberto Bianco; Gennaro Daniele; Fortunato Ciardiello; James A McCubrey; Maria Rosaria Ricciardi; Ludovica Ciuffreda; Francesco Cognetti; Agostino Tafuri; Michele Milella
Journal:  Drug Resist Updat       Date:  2007-05-07       Impact factor: 18.500

8.  A phase I trial of daily oral 4'- N -benzoyl-staurosporine in combination with protracted continuous infusion 5-fluorouracil in patients with advanced solid malignancies.

Authors:  Joseph P Eder; Rocio Garcia-Carbonero; Jeffrey W Clark; Jeffrey G Supko; Thomas A Puchalski; David P Ryan; Pamela Deluca; Antoinette Wozniak; Angela Campbell; John Rothermel; Patricia LoRusso
Journal:  Invest New Drugs       Date:  2004-04       Impact factor: 3.850

9.  Bile acid regulation of C/EBPbeta, CREB, and c-Jun function, via the extracellular signal-regulated kinase and c-Jun NH2-terminal kinase pathways, modulates the apoptotic response of hepatocytes.

Authors:  Liang Qiao; Song Iy Han; Youwen Fang; Jong Sung Park; Seema Gupta; Donna Gilfor; George Amorino; Kristoffer Valerie; Linda Sealy; John F Engelhardt; Steven Grant; Philip B Hylemon; Paul Dent
Journal:  Mol Cell Biol       Date:  2003-05       Impact factor: 4.272

10.  A selective sphingosine kinase 1 inhibitor integrates multiple molecular therapeutic targets in human leukemia.

Authors:  Steven W Paugh; Barbara S Paugh; Mohamed Rahmani; Dmitri Kapitonov; Jorge A Almenara; Tomasz Kordula; Sheldon Milstien; Jeffrey K Adams; Robert E Zipkin; Steven Grant; Sarah Spiegel
Journal:  Blood       Date:  2008-05-29       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.